Ginkgo Bioworks Holdings, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Ginkgo Bioworks Holdings, Inc. (DNA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are DNA insiders buying or selling?
In the last 12 months, Ginkgo Bioworks Holdings, Inc. insiders reported 0 open-market purchases ($0) and 16 sales ($3.7M) — net selling of $3.7M. Since October 2022, Trabud has recorded 361 Form 4 filings for DNA: 4 buys ($1.7M) and 357 sells ($193.4M).
Source: SEC EDGAR Form 4
What stands out
- No Ginkgo Bioworks Holdings, Inc. insider made an open-market purchase in the last 12 months; the 16 reported open-market sales totaled $3.7M.
Key Statistics (October 2022 – Oct 7, 2026)
Total Form 4 filings
361
SEC EDGAR
Insider filers
10
Insider buys (4)
$1.7M
Insider sells (357)
$193.4M
Insider sentiment
Net sellingNet insider flow of $191.6M in net selling since October 2022, and $3.7M in net selling over the last 12 months.
Recent DNA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 2.4K | $15.00 | $36.0K | SEC ↗ |
| Sep 16, 2026 | Christian O Henry | Director | Sale | 5.0K | $7.08 | $35.4K | SEC ↗ |
| Aug 25, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 330 | $6.98 | $2.3K | SEC ↗ |
| Jul 20, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 752 | $7.90 | $5.9K | SEC ↗ |
| May 26, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 307 | $8.33 | $2.6K | SEC ↗ |
| Apr 20, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 324 | $7.95 | $2.6K | SEC ↗ |
| Apr 14, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 33.2K | $6.41 | $212.8K | SEC ↗ |
| Apr 13, 2026 | Barry Canton | 10% Owner | Sale | 124.7K | $6.43 | $802.5K | SEC ↗ |
| Apr 13, 2026 | Reshma P. Shetty | President & Founder | Sale | 124.7K | $6.43 | $802.5K | SEC ↗ |
| Apr 10, 2026 | Reshma P. Shetty | President & Founder | Sale | 26.3K | $6.66 | $175.1K | SEC ↗ |
| Apr 10, 2026 | Barry Canton | 10% Owner | Sale | 26.3K | $6.66 | $175.1K | SEC ↗ |
| Apr 10, 2026 | Jason R Kelly | CEO & Founder | Sale | 206.8K | $6.65 | $1.4M | SEC ↗ |
| Mar 18, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 708 | $6.74 | $4.8K | SEC ↗ |
| Jan 22, 2026 | Steven P. Coen | Chief Financial Officer | Sale | 972 | $8.92 | $8.7K | SEC ↗ |
| Dec 16, 2025 | Steven P. Coen | Chief Financial Officer | Sale | 736 | $8.89 | $6.5K | SEC ↗ |
| Oct 21, 2025 | Steven P. Coen | Chief Financial Officer | Sale | 1.3K | $13.65 | $17.9K | SEC ↗ |
| Oct 3, 2025 | Steven P. Coen | Chief Financial Officer | Sale | 5.6K | $15.00 | $84.1K | SEC ↗ |
| Sep 10, 2025 | Christian O Henry | Director | Sale | 20.0K | $10.99 | $219.8K | SEC ↗ |
| Aug 26, 2025 | Steven P. Coen | Chief Financial Officer | Sale | 310 | $12.40 | $3.8K | SEC ↗ |
| Jul 21, 2025 | Steven P. Coen | Chief Financial Officer and Chief Accounting Officer | Sale | 1.1K | $9.84 | $10.7K | SEC ↗ |
| May 22, 2025 | Steven P. Coen | Chief Accounting Officer | Sale | 346 | $7.59 | $2.6K | SEC ↗ |
| May 22, 2025 | Mark E. Dmytruk | Chief Financial Officer | Sale | 706 | $7.59 | $5.4K | SEC ↗ |
| Apr 23, 2025 | Steven P. Coen | Chief Accounting Officer | Sale | 997 | $7.28 | $7.3K | SEC ↗ |
| Apr 23, 2025 | Mark E. Dmytruk | Chief Financial Officer | Sale | 1.2K | $7.28 | $9.1K | SEC ↗ |
| Mar 6, 2025 | Steven P. Coen | Chief Accounting Officer | Sale | 395 | $7.73 | $3.1K | SEC ↗ |
Showing the 25 most recent of 361 Form 4 filings for Ginkgo Bioworks Holdings, Inc..
Most active DNA insiders
- Reshma P. Shetty89 filings
- Barry Canton88 filings
- Jason R Kelly88 filings
- Mark E. Dmytruk36 filings
- Steven P. Coen26 filings
Ask anything about DNA insider activity
Use Trabud's AI agent to query Ginkgo Bioworks Holdings, Inc.'s Form 4 history in plain English — "Show me DNA CEO purchases this year" or compare it against any other ticker.
Open the AI agentDNA insider trading FAQ
Are Ginkgo Bioworks Holdings, Inc. insiders buying or selling?
In the last 12 months, Ginkgo Bioworks Holdings, Inc. insiders reported 0 open-market purchases ($0) and 16 sales ($3.7M) — net selling of $3.7M. Since October 2022, Trabud has recorded 361 Form 4 filings for DNA: 4 buys ($1.7M) and 357 sells ($193.4M). Over the full record that is net selling of $191.6M.
How many insiders trade DNA stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Ginkgo Bioworks Holdings, Inc.. The most recent filing was accepted on Oct 7, 2026.
Where does Trabud get DNA insider trading data?
All DNA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.